2025 · Phase 2a human trial
An AI-discovered molecule enters a randomised lung-disease trial
Rentosertib connected computational discovery with an early clinical evaluation.
Research publication: 2025-06-03 · English briefing: 18 September 2026
What the research found
A randomised phase 2a study evaluated the TNIK inhibitor rentosertib in seventy-one people with idiopathic pulmonary fibrosis over twelve weeks. The investigators reported safety findings and exploratory lung-function signals across dose groups. The paper described the compound as originating from a generative AI-supported discovery programme.
Where the evidence stops
The small, short study cannot establish long-term benefit or confirm a treatment for ageing. Adverse events and discontinuations remain relevant, and larger, longer trials are needed to assess clinical value.
The private-client perspective
This is a useful example of how AI can contribute to drug development without replacing its clinical stages. The important evidence is the study design, patient outcomes and safety record, not merely the use of AI upstream. A private client should distinguish a faster route to a candidate molecule from a proven faster route to a beneficial approved medicine.
Read the source
- A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial. (2025-06-03)
An independent editorial synthesis of published research, not an original NoahThera study or a personal medical recommendation. Evidence stages are identified above; cited researchers and institutions are not represented as NoahThera partners.